Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Keros Therapeutics (KROS) Return on Invested Capital (2025)

Historic Return on Invested Capital for Keros Therapeutics (KROS) over the last 5 years, with Q3 2025 value amounting to 0.06%.

  • Keros Therapeutics' Return on Invested Capital changed N/A to 0.06% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.06%, marking a year-over-year change of. This contributed to the annual value of 0.47% for FY2024, which is N/A changed from last year.
  • According to the latest figures from Q3 2025, Keros Therapeutics' Return on Invested Capital is 0.06%.
  • Keros Therapeutics' 5-year Return on Invested Capital high stood at 0.06% for Q3 2025, and its period low was 0.4% during Q3 2022.
  • For the 4-year period, Keros Therapeutics' Return on Invested Capital averaged around 0.22%, with its median value being 0.25% (2021).
  • Within the past 5 years, the most significant YoY rise in Keros Therapeutics' Return on Invested Capital was 2200bps (2021), while the steepest drop was -10200bps (2021).
  • Keros Therapeutics' Return on Invested Capital (Quarter) stood at 0.25% in 2021, then tumbled by -57bps to 0.4% in 2022, then increased by 4bps to 0.38% in 2024, then surged by 115bps to 0.06% in 2025.
  • Its Return on Invested Capital stands at 0.06% for Q3 2025, versus 0.0% for Q2 2025 and 0.0% for Q1 2025.